JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

Search

Ionis Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

83.44 -1.48

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

82.67

Max

86.64

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-252M

-129M

Pardavimai

-295M

157M

Pelno marža

-82.062

Darbuotojai

1,069

EBITDA

-254M

-103M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+14.37% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-02-18

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

1.8B

13B

Ankstesnė atidarymo kaina

84.92

Ankstesnė uždarymo kaina

83.44

Naujienos nuotaikos

By Acuity

100%

0%

335 / 352 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

Ionis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-05 23:57; UTC

Uždarbis

Naver Has Record Year Despite Weaker Final Quarter

2026-02-05 23:45; UTC

Karštos akcijos

Stocks to Watch: Amazon, Coty, Gen Digital, Roblox

2026-02-05 22:26; UTC

Uždarbis

REA Group Lifts Dividend, Announces Buyback as 1st Half Profit Rises 9% -- Update

2026-02-05 22:00; UTC

Uždarbis

REA Group Lifts Dividend, Announces Buyback as 1st Half Profit Rises 9%

2026-02-05 23:47; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-02-05 23:47; UTC

Rinkos pokalbiai

Nikkei May Fall After U.S. Tech Stock Drops -- Market Talk

2026-02-05 23:43; UTC

Rinkos pokalbiai

Gold Falls on Spillover Impact From Cryptocurrencies' Selloff -- Market Talk

2026-02-05 23:37; UTC

Rinkos pokalbiai

Glencore Shares Look Cheap After Failed Takeover Talks -- Market Talk

2026-02-05 23:20; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Amazon to Spend $200 Billion as It Accelerates AI Projects -- 5th Update

2026-02-05 23:11; UTC

Rinkos pokalbiai

Amazon CEO Confident in Return on $200B Investment -- Market Talk

2026-02-05 23:09; UTC

Uždarbis

Naver 2025 Net KRW1.820T Vs. Net KRW1.932T >035420.SE

2026-02-05 23:08; UTC

Uždarbis

Naver 2025 Oper Pft KRW2.208T Vs. Pft KRW1.979T >035420.SE

2026-02-05 23:07; UTC

Uždarbis

Naver 2025 Rev KRW12.035T Vs. KRW10.738T >035420.SE

2026-02-05 23:03; UTC

Rinkos pokalbiai
Uždarbis

REA's Update Looks Negative Despite A$200M Buyback -- Market Talk

2026-02-05 23:03; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Bitcoin Booster's $12 Billion Loss Headlines Crypto's Worst Day Since 2022 Crash -- WSJ

2026-02-05 23:00; UTC

Uždarbis

Naver 4Q Net Profit Missed FactSet-Compiled Consensus

2026-02-05 23:00; UTC

Uždarbis

Naver 4Q Net KRW164.60B Vs. Net KRW514.00B >035420.SE

2026-02-05 22:59; UTC

Uždarbis

Naver 4Q Oper Pft KRW610.60B Vs. Pft KRW542.00B >035420.SE

2026-02-05 22:59; UTC

Uždarbis

Naver 4Q Rev KRW3.195T Vs. KRW2.886T >035420.SE

2026-02-05 22:52; UTC

Uždarbis

Alphabet Stock Is Taking a Hit After Strong Earnings. Don't Panic. -- Barrons.com

2026-02-05 22:45; UTC

Uždarbis

Amazon Stock Falls Sharply on Earnings. Spending Continues to Soar. -- Barrons.com

2026-02-05 22:37; UTC

Rinkos pokalbiai

Woolworths's Profit Margin Likely Faces 2Q Squeeze -- Market Talk

2026-02-05 22:11; UTC

Uždarbis

REA Group Lifts Dividend, Announces Buyback as 1H Profit Rises 9% -- Update

2026-02-05 22:03; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Amazon to Spend $200 Billion as It Accelerates AI Projects -- 4th Update

2026-02-05 22:01; UTC

Uždarbis

Reddit Stock Jumps on Earnings. CFO Cites Modest AI Spending. -- Barrons.com

2026-02-05 21:59; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

What's Next For Rio Tinto, Glencore After Deal Talks Fail? -- Market Talk

2026-02-05 21:51; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Saylor's Strategy Posts $12 Billion Quarterly Loss on Bitcoin Selloff -- WSJ

2026-02-05 21:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Basic Materials Roundup: Market Talk

2026-02-05 21:49; UTC

Uždarbis

Why Google's Bad News Was Good News for Broadcom and Nvidia -- Barrons.com

2026-02-05 21:45; UTC

Uždarbis

REA Group Lifts Dividend, Announces Buyback as 1H Profit Rises 9%

Akcijų palyginimas

Kainos pokytis

Ionis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

14.37% į viršų

12 mėnesių prognozė

Vidutinis 97.2 USD  14.37%

Aukščiausias 110 USD

Žemiausias 89 USD

Remiantis 12 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ionis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

12 ratings

11

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

29.78 / 33.645Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Neutral Evidence

Vidutinės trukmės periodas

Very Strong Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

335 / 352 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat